Novartis completes safety review and initiates update to the Beovu prescribing information worldwide.
As part of its safety surveillance program, Novartis has been actively evaluating post-marketing cases reported as severe vision loss, retinal artery occlusion and/or vasculitis with Beovu (brolucizumab). The… read more.